icon-    folder.gif   Conference Reports for NATAP  
 
  IAS 2013: 7th IAS Conference on HIV
Pathogenesis Treatment and Prevention
June 30 - July 3 2013
Kuala Lumpur, Malaysia
Back grey_arrow_rt.gif
 
 
 
Maraviroc Safety & Efficacy in Children Aged 2-18
 
 
  Reported by Jules Levin
IAS 2013 June 30-July 3 Kuala Lumpur
 
IAS: Efficacy and Tolerability of Maraviroc for Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13)
 
Link to webcast: http://pag.ias2013.org/flash.aspx?pid=67
 
CONCLUSIONS
 
·These data suggest that in HIV-1-infected, treatment-experienced children aged 2 - <18 years, MVC (administered twice-daily) in addition to OBT was:
 
–Generally well-tolerated
 
–Effective at 48 wks, with 52% and 40% of subjects achieving HIV-1 RNA < 400 copies/mL and < 48 copies/mL, respectively
 
·Virological failure was associated with non adherence and was more frequent in adolescents (Cohort 4)
 
·Enrolment is continuing with collection of additional data, including OBT resistance, out to 5 years